Bicara Therapeutics Inc. Common Stock (BCAX) Stock
NASDAQ · BCAX
Key stats
- Market cap
- $699.06M
- Price / Earnings ratio
- -3.1x
- EPS (TTM)
- -$3.47
- Volume
- Loading
- 52-week high
- $30.99
- 52-week low
- $7.87
Source: third-party data provider, as of November 13, 2026
Compare with BCAX
Recent news

MarketBeat
Bicara Therapeutics Q2 Earnings Call Highlights
BCAXAugust 11, 2026
MarketBeat
Bicara Therapeutics Q2 Earnings Call Highlights
BCAX

The Motley Fool
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
BCAXJune 13, 2026
The Motley Fool
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
BCAX

MarketBeat
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
BCAXMay 22, 2026
MarketBeat
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
BCAX

MarketBeat
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
BCAXMay 14, 2026
MarketBeat
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
BCAX
Technical indicators
- RSI 14
- 35.88
- MACD 12/26/9
- -2.50
- EMA 9 of MACD
- -2.53
- MACD histogram
- 0.03
- SMA 50
- $17.37
- Price below SMA 50
- EMA 50
- $16.22
- Price below EMA 50
- SMA 200
- $20.90
- Price below SMA 200
- EMA 200
- $19.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Strong Sell1
Sell0
Hold0
Buy6
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
612M404M202M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-137.9M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Bicara Therapeutics Q2 Earnings Call Highlights
BCAXAugust 11, 2026
MarketBeat
Bicara Therapeutics Q2 Earnings Call Highlights
BCAX

The Motley Fool
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
BCAXJune 13, 2026
The Motley Fool
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
BCAX

MarketBeat
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
BCAXMay 22, 2026
MarketBeat
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
BCAX

MarketBeat
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
BCAXMay 14, 2026
MarketBeat
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
BCAX

MarketBeat
Bicara Therapeutics Q1 Earnings Call Highlights
BCAXMay 11, 2026
MarketBeat
Bicara Therapeutics Q1 Earnings Call Highlights
BCAX

Zacks Investment Research
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
BCAXApril 1, 2026
Zacks Investment Research
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
BCAX

The Motley Fool
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
BCAXMarch 30, 2026
The Motley Fool
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
BCAX

The Motley Fool
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
BCAXMarch 26, 2026
The Motley Fool
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
BCAX

Proactive Investors
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
BCAXMarch 25, 2026
Proactive Investors
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
BCAX
About Bicara Therapeutics Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees103
CEODr. Claire Mazumdar Clemon M.B.A., Ph.D.
IPO DateSep 13, 2024
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director | 1989 |
| Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director | 1977 |
| Ms. Jennifer Larson | CFO, Treasurer & Principal Accounting Officer | 1975 |
| Ms. Rachel Frank | Vice President of Investor Relations and Corporate Communications | — |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary | 1972 |
| Ms. Pauline Dufresne | Chief People Officer | — |
| Ms. Rachel Salazar | SVP of R&D Strategy and Operations | — |
| Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain | — |
| Ms. Angela Windt | VP & Head of Regulatory Affairs | — |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs | — |
Fundamentals
Valuation
Price-to-book value1.65
Profitability
Return on Equity-42.00%
Return on Assets-39.00%
EBITDA$-183.91M
Trading
Average volume2,030,404
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 35.88
- MACD 12/26/9
- -2.50
- EMA 9 of MACD
- -2.53
- MACD histogram
- 0.03
- SMA 50
- $17.37
- Price below SMA 50
- EMA 50
- $16.22
- Price below EMA 50
- SMA 200
- $20.90
- Price below SMA 200
- EMA 200
- $19.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
86% Buy
0% Hold
14% Sell
Analyst price target
- Low
- $8.00
- Average
- $30.43
- High
- $43.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +8.8 | -3.1 | -13.4 | -12.9 | ||||||||
| 2025 | -25.5 | +8.1 | +2.6 | +13.5 | -37.1 | -6.2 | +17.4 | +13.4 | +32.7 | -2.2 | +16.1 | -2.9 |
| 2026 | +2.6 | +0.1 | +13.1 | +5.3 | +0.4 | +44.0 | -6.3 | -10.2 | -20.5 | -49.8 | +32.8 |
Compare stocks
Market cap
$699.06M
-
-
-
Price / Earnings ratio
-3.10
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
2,030,404
-
-
-
Earnings per share
$-3.47
-
-
-



